Chronic recurrent multifocal osteomyelitis/ chronic nonbacterial osteomyelitis (CRMO/CNO)

Surveillance of chronic recurrent multifocal osteomyelitis/ chronic nonbacterial osteomyelitis (CRMO/CNO) commenced in October 2020. It is being led by Dr Chenqu Suo, winner of the Sir Peter Tizard Bursary 2018-19. This study intends to find out how common CRMO/CNO is, and who is involved in the care of CRMO/CNO patients. This will help to guide planning in healthcare services. Moreover, by looking at the existing treatments patients receive and their outcome, the study will allow us to understand the different treatments being used across the country, the short-term outlook, and complications.

Overview

Chronic recurrent multifocal osteomyelitis, also known as chronic nonbacterial osteomyelitis (CNO), is a rare autoinflammatory bone disease. It is characterised by bone pain and swelling. CRMO/CNO occurs primarily in children and teenagers. There is a spectrum of severity with mild cases only requiring nonsteroidal anti-inflammatory drugs (NSAIDs) for disease control, compared to severe cases with serious complications such as vertebral fracture, who require multiple medications such as bisphosphonate and immunosuppressants.

Though first described over four decades ago, we still do not know how common CRMO/CNO is. Therefore, this study intends to determine the incidence of CRMO/CNO in the UK and the Republic of Ireland. We will also analyse the disease epidemiology, clinical and radiological features, how CRMO/CNO is managed currently, and two-year outcomes.

Investigators

Dr Chenqu Suo
Addenbrooke’s Hospital
Hills Road
Cambridge CB2 0QQ
Email: add-tr.crmostudy@nhs.net